An Open Label, Multicenter Trial Assessing the Acceptability of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Patients With Type 2 Diabetes and Dyslipidemia

Trial Profile

An Open Label, Multicenter Trial Assessing the Acceptability of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Patients With Type 2 Diabetes and Dyslipidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2012

At a glance

  • Drugs Fenofibrate/metformin (Primary)
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories; Solvay Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2010 Actual patient number (29) added as reported by ClinicalTrials.gov.
    • 31 Aug 2007 Status changed from in progress to completed.
    • 03 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top